Skip to content

PP&E (Net) at other companies

HRO
HarrowHROW
$3.13M-12.3%
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
$1.13M-2.8%
Ocular Therapeutix logo
Ocular TherapeutixOCUL
$18.43M+70.9%
Stoke Therapeutics, Inc. logo
Stoke Therapeutics, Inc.STOK
$3.4M-6.0%
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
$239M-8.4%
Arcutis Biotherapeutics, Inc. logo
Arcutis Biotherapeutics, Inc.ARQT
$1.04M-30.5%

Segments

By geography

See full
CH$53.2M-20.1%
US$32.1M-9.8%

Other financials

Income statement

See full
Operating income-$59.8M-1.2%
Net income-$58.2M-1.2%
EPS (diluted)-$0.94+13.8%

Balance sheet

See full
Cash & equivalents$169.5M+22.1%
Total debt$56.0M-17.2%
Total equity$112.1M+3.0%
Total assets$306.0M+2.7%

Cash flow

See full
Operating cash flow-$40.0M-37.6%
CapEx$942.0K+249%
Free cash flow-$41.0M-39.5%

Valuation

See full
Market cap$2.32B+1,477%
Enterprise value$2.2B+2,798%

Returns & leverage

See full
Return on equity-208.8%+2,306pp
Debt / equity0.5×-0.1×
Current ratio3.5×-1.1×

Where this comes from

Reported directly by Kodiak Sciences Inc in its filing.

Tagged under the XBRL concept us-gaap:PropertyPlantAndEquipmentNet.

The official record: Kodiak Sciences Inc’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Kodiak Sciences Inc's pp&e (net).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Kodiak Sciences Inc's PP&E (net)?
Kodiak Sciences Inc (KOD) reported PP&E (net) of $81.51M in Q1 2026.
How has Kodiak Sciences Inc's PP&E (net) changed year-over-year?
Kodiak Sciences Inc's PP&E (net) decreased by 16.7% year-over-year, from $97.9M to $81.51M.
What is the long-term trend for Kodiak Sciences Inc's PP&E (net)?
Over 5 years (2020 to 2025), Kodiak Sciences Inc's PP&E (net) has grown at a 75.4% compound annual growth rate (CAGR), from $5.14M to $85.26M.
What does PP&E (net) mean?
Total property, plant, and equipment minus accumulated depreciation — the net book value of all tangible long-lived assets.